Psyence Biomedical PBM
NASDAQ PBM
$4.32 -0.20 (-4.31%)
As of: Oct 22, 2026 · 2:10 PM EDT

Psyence Biomedical (PBM) Non-Current Deffered Revenue (2022 - 2023)

Updated

Psyence Biomedical's Non-Current Deffered Revenue came in at $13.1 million for the quarter ended Sep 30, 2023.

Analysis

Psyence Biomedical (PBM) Non-Current Deffered Revenue (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,167.12 Bn 1,135.70 Bn 19.71 Bn -
2 Johnson & Johnson 647.48 Bn 567.35 Bn 17.30 Bn -
3 AbbVie 502.73 Bn 475.84 Bn 12.70 Bn -
4 Merck 363.86 Bn 318.23 Bn 12.21 Bn -
5 Novartis Ag 303.31 Bn 267.30 Bn 11.24 Bn -
6 Astrazeneca 269.08 Bn 242.77 Bn 12.86 Bn -
7 Amgen 242.07 Bn 197.46 Bn 7.24 Bn -
8 Gilead Sciences 194.93 Bn 169.12 Bn 6.22 Bn -
9 Pfizer 172.42 Bn 119.07 Bn 10.94 Bn -
10 Psyence Biomedical 2.39 Mn -20.27 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 13.10 Mn
Dec 31, 2022 13.10 Mn
API Access

Psyence Biomedical Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=PBM&period=max&api_key=YOUR_API_KEY